Kymera Therapeutics
KYMR
Kymera Therapeutics (KYMR) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Raymond James | Initiated Coverage | Outperform | $140.00 | Oct 9, 2026 |
| Citigroup | Maintained | Buy | $150.00 from $135.00 | Oct 5, 2026 |
| Stifel | Maintained | Buy | $152.00 from $132.00 | Sep 22, 2026 |
| B of A Securities | Maintained | Buy | $144.00 from $123.00 | Sep 14, 2026 |
| Wolfe Research | Upgraded | Peer Perform → Outperform | — | Sep 10, 2026 |
| Guggenheim | Maintained | Buy | $170.00 from $135.00 | Aug 31, 2026 |
| Wells Fargo | Maintained | Overweight | $151.00 from $116.00 | Aug 27, 2026 |
| Barclays | Maintained | Overweight | $139.00 from $133.00 | Aug 6, 2026 |
| Deutsche Bank | Initiated Coverage | Hold | $120.00 | Jul 30, 2026 |
| Guggenheim | Maintained | Buy | $135.00 from $125.00 | Jul 28, 2026 |
| Mizuho | Maintained | Outperform | $140.00 from $120.00 | Jul 16, 2026 |
| RBC Capital | Downgraded | Outperform → Sector Perform | $115.00 from $106.00 | Jul 13, 2026 |
| B of A Securities | Maintained | Buy | $125.00 from $110.00 | Jun 30, 2026 |
| B. Riley Securities | Maintained | Buy | $155.00 from $117.00 | Jun 29, 2026 |
| Truist Securities | Maintained | Buy | $136.00 from $116.00 | Jun 29, 2026 |
| Canaccord Genuity | Maintained | Buy | $129.00 from $106.00 | Jun 26, 2026 |
| BTIG | Maintained | Buy | $134.00 | Jun 25, 2026 |
| Canaccord Genuity | Initiated Coverage | Buy | $106.00 | May 6, 2026 |
| Jefferies | Initiated Coverage | Buy | $110.00 from $122.00 | Mar 16, 2026 |
| UBS | Maintained | Buy | $128.00 from $90.00 | Mar 3, 2026 |
Frequently asked questions
What is the latest analyst rating on KYMR?
On Oct 9, 2026, Raymond James initiated coverage of Kymera Therapeutics at Outperform with a price target of $140.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.